Double-blind Randomized study comparing Baloxavir Marboxil to Peramivir in pediatric patients with Influenza

Double-blind Randomized study comparing Baloxavir Marboxil to Peramivir in pediatric patients with Influenza - Double-blind Randomized study comparing Baloxavir Marboxil to Peramivir in pediatric patients with Influenza

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000034870

Enrollment

Registered

2018-11-14

Start date

2018-11-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Influenza

Interventions

Baloxavir marboxil Peramivir

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)axillary temperature more than 37.5 degree 2)a positive rapid antigen test for influenza virus 3)a symptom duraiton of no more than 36 hours 4)hospitalized patient 5)body weight more than 10kg

Exclusion criteria

Exclusion criteria: 1)patients who have suffered from bacterial infection or other viral infection within one week from the start of the study 2)patients who received recipes of Baloxavir marboxil, Oseltamivir, Zanavivir, Laninavir, Peramivir within 4 weeks from the start of the study

Design outcomes

Primary

Measure	Time frame
The time to alleviation of influenza symptoms The time to resolution of fever	—

Secondary

Measure	Time frame
The changes from baseline in infectious virus and viral RNA titers	—

Countries

Japan

Contacts

Public ContactKentaro Kato

The Tazuke Kofukai Medical Research Institute Kitano Hospital Department of Pediatrics

kenkato100@gmail.com+81-6-6312-1221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026